Home > Insider Trading > Filing (0001062993-21-007818)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
748592	Brooklyn Immunotherapeutics Inc.	BTX	Pharmaceutical Preparations (2834)	311103425

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1234956	Iii P George Denny	C/O Locke Lord Llp 111 Huntington Avenue Boston MA 02199		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-07-06	75,000	$16.06	4,775,117	No	4	S	Indirect	By Denny Family Partners II, LLC
Common Stock	Acquisiton	2021-07-08	1	$14.35	1	No	4	P	Indirect	By Spouse
Common Stock	Acquisiton	2021-07-09	1	$14.11	2	No	4	P	Indirect	By Spouse
Common Stock	Acquisiton	2021-07-14	1	$11.99	3	No	4	P	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Denny Family Partners II, LLC
No	4	P	Indirect	By Spouse
No	4	P	Indirect	By Spouse
No	4	P	Indirect	By Spouse

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	34,585	Indirect	By George P. Denny Trust 6/11/81
Common Stock	4,094	Direct

Footnotes

The sale by Denny Family Partners II, LLC of BTX Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 3 shares, with the purchase of 3 shares of BTX Common Stock by the reporting person's spouse, also reported herein. The reporting person has agreed to pay to BTX, upon settlement of the sale, $8.78, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.41, inclusive. The reporting person undertakes to provide to Brooklyn ImmunoTherapeutics, Inc., any security holder of Brooklyn ImmunoTherapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2.
The reporting person disclaims beneficial ownership of the shares held by Denny Family Partners II, LLC except to the extent of his pecuniary interest therein.